104,627 Shares in Alignment Healthcare, Inc. $ALHC Acquired by Campbell Newman Asset Management Inc.

Campbell Newman Asset Management Inc. purchased a new position in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) in the 1st quarter, Holdings Channel reports. The firm purchased 104,627 shares of the company’s stock, valued at approximately $1,844,000.

Other large investors also recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in shares of Alignment Healthcare by 167.3% in the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock valued at $193,516,000 after purchasing an additional 6,940,277 shares in the last quarter. Invesco Ltd. grew its stake in shares of Alignment Healthcare by 122.3% during the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after purchasing an additional 2,294,739 shares in the last quarter. Capital World Investors purchased a new position in Alignment Healthcare in the fourth quarter valued at $44,203,000. Loomis Sayles & Co. L P purchased a new position in Alignment Healthcare in the fourth quarter valued at $44,162,000. Finally, Danica Pension Livsforsikringsaktieselskab purchased a new position in Alignment Healthcare in the fourth quarter valued at $39,500,000. 86.19% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alignment Healthcare

In related news, insider Hyong Kim sold 35,951 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $19.86, for a total value of $713,986.86. Following the completion of the sale, the insider owned 331,750 shares in the company, valued at $6,588,555. This represents a 9.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Christopher J. Joyce sold 18,013 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $17.79, for a total transaction of $320,451.27. Following the sale, the insider owned 305,451 shares of the company’s stock, valued at approximately $5,433,973.29. This represents a 5.57% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 1,299,064 shares of company stock valued at $25,478,457. 5.20% of the stock is currently owned by insiders.

Alignment Healthcare Price Performance

Shares of NASDAQ ALHC opened at $21.86 on Monday. The business has a 50-day moving average price of $18.66 and a 200 day moving average price of $19.48. The stock has a market cap of $4.52 billion, a PE ratio of 242.89, a price-to-earnings-growth ratio of 2.95 and a beta of 1.14. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 1.56. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The firm’s revenue was up 33.3% compared to the same quarter last year. Equities research analysts forecast that Alignment Healthcare, Inc. will post 0.2 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Zacks Research raised Alignment Healthcare from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 28th. Barclays dropped their price objective on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Weiss Ratings raised Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. KeyCorp restated an “overweight” rating on shares of Alignment Healthcare in a research note on Wednesday, June 10th. Finally, UBS Group boosted their target price on Alignment Healthcare from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.30.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.